about
Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imagingNeuropharmacological effects of Nigella sativamiRNA profiling for biomarker discovery in multiple sclerosis: from microarray to deep sequencingBiomarkers in Multiple Sclerosis: An Up-to-Date OverviewA Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future PerspectivesBiomarkers of treatment response in multiple sclerosisDiagnostic biomarkers in multiple sclerosis.Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.Clinical and imaging metrics for monitoring disease progression in patients with multiple sclerosis.Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis.Cerebrospinal fluid proteome profile in multiple sclerosis.Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls.Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage.Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis.Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosisA consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosisDysregulation of chemo-cytokine production in schizophrenic patients versus healthy controlsAn N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis.Computational classifiers for predicting the short-term course of Multiple sclerosis.Developing therapeutics for the treatment of multiple sclerosisThe immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis.Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.Paediatric UK demyelinating disease longitudinal study (PUDDLS).The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosisCerebrospinal fluid interleukin-6 in central nervous system inflammatory diseasesConformational epitopes of myelin oligodendrocyte glycoprotein are targets of potentially pathogenic antibody responses in multiple sclerosis.A Population Approach to Characterize Interferon Beta-1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple Sclerosis.Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.Analysis of Lymphocytic DNA Damage in Early Multiple Sclerosis by Automated Gamma-H2AX and 53BP1 Foci Detection: A Case Control Study.Utility of CSF Cytokine/Chemokines as Markers of Active Intrathecal Inflammation: Comparison of Demyelinating, Anti-NMDAR and Enteroviral EncephalitisToward biomarkers in multiple sclerosis: new advances.The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis.Interferon-beta treatment for multiple sclerosis.Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases.Texture analysis improves level set segmentation of the anterior abdominal wall.Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients.Proteomic strategies in multiple sclerosis and its animal models2D DIGE of the cerebrospinal fluid proteome in neurological diseases.
P2860
Q24645501-29586ACB-B5A1-4185-9AA1-1D297E71B372Q26744248-212843A7-FF0E-4794-8911-A4EA0ABC2314Q26852074-C4C704FD-9BB2-4F08-A49F-CA3F2BA9F5C0Q27496017-060EA415-05AC-4A9B-968E-693FA1ADFABDQ28068709-B2BF0021-C52E-4BA5-9EAB-270E8259FB9EQ28305094-42BF7797-E34D-47AF-B9B1-BDE3EE7AE58EQ30598338-EE11B8DC-0C96-4EDD-B1FB-585EBC983B0FQ30712257-7C655E47-6ED7-4EC9-9A5E-70780902DBC3Q31037055-EDB33956-591D-4BD7-AF53-C6F349239DB5Q33243924-C12816DA-31E1-4FA7-B4E3-5F0B0BDE0AB2Q33299647-F2A8C93E-456E-461E-BB69-07427E312A2AQ33510154-81838FB0-38B6-4652-BA8D-F23581B3843FQ33513478-B919D006-7CBE-4ABB-881B-864EE90887B0Q33625018-2A69CE9B-F36C-4770-A213-56E726060E48Q33693097-B5AFCE79-DC9B-452D-8041-3F312758720EQ33731693-320E9396-9AF8-4A62-AC88-4000F5D3C25FQ33764503-70FC384F-5D89-494A-A519-2F435AB976D9Q33803377-609E72AD-B6F1-4317-BE05-EA7541A4B24CQ33900554-9A601770-7DC1-4AAC-9F52-6DAAB230C315Q33925740-BD01C305-867B-4B68-AFAB-D928A3F412CAQ33946995-D1427F67-D51C-447B-AB9D-3170B5A017EDQ33960847-029DA13E-79EC-4CC5-B6C8-7CC21274FAA2Q33965239-15AEF100-D161-4AAF-81BC-21E7B5E35C0DQ33974317-9F01B947-9B43-40E4-BE05-0E5B628E7597Q34890688-29731B4D-6F13-423F-9B7F-749EF49E17CDQ34981487-454DB26B-FF1C-43FB-9E60-982CB52D7AF9Q35614751-74739268-024B-41EE-A3C2-ED9AE4623453Q35676048-EE6DB418-9F08-423C-B081-F06B20D5D60CQ35697927-C595BA5C-779B-449B-8F83-0E66A9658071Q35907244-3077941C-2CA6-4D78-A1DB-B4E634036E69Q36117017-5459A37B-E9D0-44BB-ADF9-BDB2C0B206FFQ36492380-81D537E7-454B-42B2-85C3-9ABDD873BF18Q36748094-80908F61-89FD-4960-BC73-65C8C271A289Q36887316-B8C2DD23-09A3-4A8F-900F-A45C6AD1EE01Q36963178-9316FACC-8146-4C50-96AD-0E875064D20AQ37206262-D199666E-7CF9-4FE9-BEA6-B4FAB6770D0CQ37337093-60BBE62F-EBD2-409F-BE10-0D35A9EA3779Q37343069-37EC5CCD-2708-41B4-AEE8-2E7883F3229EQ37347220-54E83848-E6A6-45EF-9E75-5417ED2211E6Q37685107-D853E400-1EAC-4B64-8F3A-B814AD384895
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Development of biomarkers in multiple sclerosis.
@ast
Development of biomarkers in multiple sclerosis.
@en
type
label
Development of biomarkers in multiple sclerosis.
@ast
Development of biomarkers in multiple sclerosis.
@en
prefLabel
Development of biomarkers in multiple sclerosis.
@ast
Development of biomarkers in multiple sclerosis.
@en
P356
P1433
P1476
Development of biomarkers in multiple sclerosis.
@en
P2093
Bibiana Bielekova
Roland Martin
P304
P356
10.1093/BRAIN/AWH176
P407
P577
2004-06-04T00:00:00Z